Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims/hypothesisWe previously reported that obese individuals with the metabolic syndrome (at risk), compared with obese individuals without the metabolic syndrome (healthy obese), have elevated serum AGEs that strongly correlate with insulin resistance, oxidative stress and inflammation. We hypothesised that a diet low in AGEs (L-AGE) would improve components of the metabolic syndrome in obese individuals, confirming high AGEs as a new risk factor for the metabolic syndrome.MethodsA randomised 1 year trial was conducted in obese individuals with the metabolic syndrome in two parallel groups: L-AGE diet vs a regular diet, habitually high in AGEs (Reg-AGE). Participants were allocated to each group by randomisation using random permuted blocks. At baseline and at the end of the trial, we obtained anthropometric variables, blood and urine samples, and performed OGTTs and MRI measurements of visceral and subcutaneous abdominal tissue and carotid artery. Only investigators involved in laboratory determinations were blinded to dietary assignment. Effects on insulin resistance (HOMA-IR) were the primary outcome.ResultsSixty-one individuals were randomised to a Reg-AGE diet and 77 to an L-AGE diet; the data of 49 and 51, respectively, were analysed at the study end in 2014. The L-AGE diet markedly improved insulin resistance; modestly decreased body weight; lowered AGEs, oxidative stress and inflammation; and enhanced the protective factors sirtuin 1, AGE receptor 1 and glyoxalase I. The Reg-AGE diet raised AGEs and markers of insulin resistance, oxidative stress and inflammation. There were no effects on MRI-assessed measurements. No side effects from the intervention were identified. HOMA-IR came down from 3.1 ± 1.8 to 1.9 ± 1.3 (p < 0.001) in the L-AGE group, while it increased from 2.9 ± 1.2 to 3.6 ± 1.7 (p < 0.002) in the Reg-AGE group.Conclusions / interpretationL-AGE ameliorates insulin resistance in obese people with the metabolic syndrome, and may reduce the risk of type 2 diabetes, without necessitating a major reduction in adiposity. Elevated serum AGEs may be used to diagnose and treat ‘at-risk’ obesity.Trial registrationClinicalTrials.gov NCT01363141FundingThe study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (DK091231)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Increasing Prevalence of the Metabolic Syndrome Among U.S. Adults
Ford, E. S., Giles, W. H., & Mokdad, A. H. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2444 · Cited by 1,488
Chowdhury, R., Warnakula, S., Kunutsor, S., Crowe, F., Ward, H. A., Johnson, L., Franco, O. H., Butterworth, A. S., Forouhi, N. G., Thompson, S. G., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1788 · Cited by 1,139
Increased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950
Metabolically healthy obesity: Epidemiology, mechanisms, and clinical implications
Stefan, N., Häring, H.-U., Hu, F. B., & Schulze, M. B. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70062-7 · Cited by 857
Guarente, L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100831 · Cited by 510
Scheijen, J. L. J. M., Clevers, E., Engelen, L., Dagnelie, P. C., Brouns, F., Stehouwer, C. D. A., & Schalkwijk, C. G. (2016) · Food Chemistry · doi:10.1016/j.foodchem.2015.06.049 · Cited by 343 · cited 1×
“AGEsmay be estimated by immunochemical (ELISA) [25, 26, 37], chromatographic and mass-spectroscopy methods [18, 38].”
Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes
Uribarri, J., Cai, W., Ramdas, M., Goodman, S., Pyzik, R., Chen, X., Zhu, L., Striker, G. E., & Vlassara, H. (2011) · Diabetes Care · doi:10.2337/dc11-0091 · Cited by 320 · cited 3×
“By comparison, worsening insulin resistance and markers of oxidative stress and inflammation in the Reg-AGE group, also noted in shorter trials [17], were possibly due to an expanding net AGE pool from both exogenous and endogenous sources.”
Self-citation
Cited by
Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives
Khalid, M., Petroianu, G., & Adem, A. (2022) · Biomolecules · doi:10.3390/biom12040542 · Cited by 879
The sirtuin family in health and disease
Wu, Q.-J., Zhang, T.-N., Chen, H.-H., Yu, X.-F., Lv, J.-L., Liu, Y.-Y., Liu, Y.-S., Zheng, G., Zhao, J.-Q., Wei, Y.-F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01257-8 · Cited by 862
Dietary advanced glycation end products and their relevance for human health
Nowotny, K., Schröter, D., Schreiner, M., & Grune, T. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.06.005 · Cited by 255
Aragno, M., & Mastrocola, R. (2017) · Nutrients · doi:10.3390/nu9040385 · Cited by 239
“Though, the reduction of dietary (exogenous) AGEs in type 2 diabetes or obese patients, without modification of the total calories intake, has also been demonstrated to be effective in amelioration of insulin sensitivity, with reduction of inflammatory markers and restoration of AGEs detoxifying systems and mitochondr…”
BackgroundRole of advanced glycation end products in carcinogenesis and their therapeutic implications
Schröter, D., & Höhn, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190130145549 · Cited by 126
Metadata
- Authors
- Vlassara, H., Cai, W., Tripp, E., Pyzik, R., Yee, K., Goldberg, L., Tansman, L., Chen, X., Mani, V., Fayad, Z. A., Nadkarni, G. N., Striker, G. E., He, J. C., & Uribarri, J.
- Venue
- Diabetologia
- Published
- 2016-07-29
- Volume
- 59
- Issue
- 10
- Pages
- 2181-2192
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2479063120
- Cited by
- 143
- References
- 12
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial. https://app.cochat.ai/papers/10.1007/s00125-016-4053-x
- The paper
- Vlassara, H., Cai, W., Tripp, E., Pyzik, R., Yee, K., Goldberg, L., Tansman, L., Chen, X., Mani, V., Fayad, Z. A., Nadkarni, G. N., Striker, G. E., He, J. C., & Uribarri, J. (2016). Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial. Diabetologia. https://doi.org/10.1007/s00125-016-4053-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.